Brief: Australian Clinical Labs Responds To Healius' Target's Statement
22/05/2023 02:37
May 22 (Reuters) - Australian Clinical Labs Ltd
ACL.AX :
* RESPONSE TO HEALIUS' TARGET'S STATEMENT
* OFFERED MEETING WITH HEALIUS BOARD TO DISCUSS THE
RATIONALE FOR
OFFER, BUT HEALIUS BOARD DECLINED TO TAKE UP OFFER
* CONTINUES TO BELIEVE PROPOSED MERGER REPRESENTS MOST VALUE
ACCRETIVE OPTION TO HEALIUS SHAREHOLDERS
Source text for Eikon: ID:nASXbYJsX8
Further company coverage: ACL.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Healius
See all newsAustralia's Healius rises on sale of unit Agilex; Jefferies lifts PT
Brief: Healius To Sell Agilex Biolabs To Novotech
Australia's Healius rises on sale of unit Agilex Biolabs to Novotech Health
Brief: Healius Requests Trading Halt
Brief: Healius Expects To Achieve T27 Target Of Mid-To-High Single-Digit EBIT Margins By Dec 2028